Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > CD8+ TiLs and T-cell exhaustion

<< Previous

Bullboard Posts

Next >>

Comment by Noteableon Mar 17, 2024 9:44pm

85 Views

Post# 35937613

RE:RE:CD8+ TiLs and T-cell exhaustion

The road ahead

Cancer immunotherapy represents a new paradigm in cancer care. The approach is already transforming the lives of some patients – and holds immense promise for the future.

https://www.technologynetworks.com/cancer-research/articles/harnessing-the-power-of-the-immune-system-advances-in-cancer-immunotherapy-380857

<< Previous

Bullboard Posts

Next >>

Two micro-cap stocks with strong fundamentals